lidocaine has been researched along with Amaurosis in 38 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Excerpt | Relevance | Reference |
---|---|---|
"This case report describes an uncommon complication (blindness) occurring after an inadvertent overdosage of a frequently used local anesthetic (lidocaine) during a regional anesthetic procedure." | 7.71 | Temporary bilateral blindness after acute lidocaine toxicity. ( Sawyer, RJ; von Schroeder, H, 2002) |
"Temporary amaurosis occurred after retrobulbar injection of lidocaine in 12 cases of antiglaucoma surgery in 4 years, and 10 of the patients were of late glaucoma." | 7.68 | [Temporary amaurosis from retrobulbar lidocaine injection in late glaucoma patients]. ( Mo, XJ, 1991) |
"Implantation of an IOL at the time of cataract extraction under combined systemic ketamine and peribulbar lidocaine anesthesia appeared to be well tolerated and produced significant visual improvement in pediatric patients in Nepal." | 3.72 | Pediatric cataract surgery in Nepal. ( Gurung, R; Paudyal, G; Reddy, H; Ruit, S; Tabin, G; Thakur, J; Thapa, S; Wilson, ME, 2004) |
"This case report describes an uncommon complication (blindness) occurring after an inadvertent overdosage of a frequently used local anesthetic (lidocaine) during a regional anesthetic procedure." | 3.71 | Temporary bilateral blindness after acute lidocaine toxicity. ( Sawyer, RJ; von Schroeder, H, 2002) |
"Temporary amaurosis occurred after retrobulbar injection of lidocaine in 12 cases of antiglaucoma surgery in 4 years, and 10 of the patients were of late glaucoma." | 3.68 | [Temporary amaurosis from retrobulbar lidocaine injection in late glaucoma patients]. ( Mo, XJ, 1991) |
"A transient, ipsilateral central retinal artery occlusion and contralateral amaurosis developed following retrobulbar injection of 2% lidocaine and 0." | 3.67 | Transient central retinal artery occlusion and contralateral amaurosis after retrobulbar anesthetic injection. ( Brod, RD, 1989) |
"Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported." | 3.66 | Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting corticosteroid suspensions in combination with other drugs: I. Clinical studies. ( Havener, WH; McGrew, RN; Wilson, RS, 1978) |
"Intraoperative amaurosis was determined as that a patient could not see any light from their operative eye." | 1.56 | Correlation between sub-Tenon's anesthesia and transient amaurosis during ophthalmic surgery. ( Chen, H; Chen, W; Huang, D; Huang, Z; Lin, G; Shi, Y; Wang, Y; Zhang, G; Zhang, Q; Zheng, D, 2020) |
"The occurrence of amaurosis during ophthalmic anesthesia is well known." | 1.46 | Change in flash visual evoked potentials in New Zealand albino rabbits after sub-tenon's anesthesia. ( Brelen, M; Chen, H; Chen, W; Jhanji, V; Lin, H; Wu, X; Zhang, G, 2017) |
"Our report describes a case of temporary bilateral blindness in a patient after undergoing mitral valve replacement with a mechanical prosthesis and coronary artery bypass grafting." | 1.37 | Transient bilateral blindness in a patient after cardiac surgery. ( Bolman, RM; Dibardino, DJ; Tchantchaleishvili, V, 2011) |
"We report a case of transient blindness, part of a TURP syndrome, in a 65 year old man undergoing TUR of the prostate under centro-neuron block." | 1.30 | Loss of vision: a manifestation of TURP syndrome. A case report. ( Bakhameez, HS; Khalaf, MM; Khan, RK; Khan-Ghori, SN, 1998) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 13 (34.21) | 18.7374 |
1990's | 5 (13.16) | 18.2507 |
2000's | 8 (21.05) | 29.6817 |
2010's | 11 (28.95) | 24.3611 |
2020's | 1 (2.63) | 2.80 |
Authors | Studies |
---|---|
Shi, Y | 1 |
Huang, Z | 2 |
Chen, W | 3 |
Zhang, G | 3 |
Huang, D | 2 |
Lin, G | 2 |
Wang, Y | 1 |
Chen, H | 2 |
Zheng, D | 2 |
Zhang, Q | 1 |
Lartey, S | 1 |
Armah, P | 1 |
Ampong, A | 1 |
Wu, X | 1 |
Jhanji, V | 1 |
Lin, H | 1 |
Brelen, M | 1 |
Matharu, KS | 1 |
Smith, SV | 1 |
Lee, AG | 1 |
Chia, K | 1 |
Teoh, S | 1 |
Falzon, K | 1 |
Guerin, MB | 1 |
Fulcher, T | 1 |
Al-Sandook, T | 1 |
Al-Saraj, A | 1 |
Cho, HK | 1 |
Jee, D | 1 |
Lee, WK | 1 |
Shin, CH | 1 |
Ryu, JW | 1 |
Çok, OY | 1 |
Eker, HE | 1 |
Cantürk, S | 1 |
Yaycioğlu, R | 1 |
Ariboğan, A | 1 |
Arslan, G | 1 |
Tchantchaleishvili, V | 1 |
Dibardino, DJ | 1 |
Bolman, RM | 1 |
Tasi, WC | 1 |
Petersen-Jones, SM | 1 |
Huang, PY | 1 |
Lin, CT | 1 |
Bektas, D | 1 |
Kul, N | 1 |
Akyol, N | 1 |
Ural, A | 1 |
Caylan, R | 1 |
Ahmad, KE | 1 |
McColl, DC | 1 |
Duncan, M | 1 |
Lueck, CJ | 1 |
Lake, D | 1 |
Mearza, A | 1 |
Ionides, A | 1 |
Thakur, J | 1 |
Reddy, H | 1 |
Wilson, ME | 1 |
Paudyal, G | 1 |
Gurung, R | 1 |
Thapa, S | 1 |
Tabin, G | 1 |
Ruit, S | 1 |
Björkman, A | 1 |
Rosén, B | 1 |
Lundborg, G | 1 |
Bricknell, PP | 1 |
Middleton, HG | 1 |
Hollingsworth, A | 1 |
Evans, EM | 1 |
Plate, S | 1 |
Asboe, S | 1 |
Goldenberg, AS | 1 |
Hamel, P | 1 |
Boghen, D | 1 |
Khan-Ghori, SN | 1 |
Khalaf, MM | 1 |
Khan, RK | 1 |
Bakhameez, HS | 1 |
Mitchell, SJ | 1 |
Benson, M | 1 |
Vadlamudi, L | 1 |
Miller, P | 1 |
Maaranen, TH | 1 |
Mäntyjärvi, MI | 1 |
Sawyer, RJ | 1 |
von Schroeder, H | 1 |
Wilson, RS | 1 |
Havener, WH | 1 |
McGrew, RN | 1 |
Mo, XJ | 1 |
Verma, L | 1 |
Arora, R | 1 |
Kumar, A | 1 |
Rettinger, G | 1 |
Christ, P | 1 |
Brod, RD | 1 |
Nandrup, E | 1 |
Kambic, V | 1 |
Kolar, C | 1 |
Krasecec, J | 1 |
Judit, BS | 1 |
Gahlaut, DS | 1 |
Sikka, KK | 1 |
Olurin, O | 1 |
Ellis, PP | 1 |
Hanisch, J | 1 |
Födö, V | 1 |
Krüger, KE | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.27 |
Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.57 |
Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.09 |
Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.07 |
Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 6.3 |
Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -10.98 |
Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.02 |
Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.04 |
Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.71 |
Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 1.23 |
Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.20 |
Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.95 |
Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -6.70 |
Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -7.12 |
Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.39 |
Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.67 |
Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.46 |
Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -3 |
Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.15 |
Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 2.46 |
Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | Participants (Count of Participants) |
---|---|
Lidocaine | 87 |
Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) | |
---|---|---|
1 year Change Work Activities | 1 year Change General health perception | |
Lidocaine | -1.37 | -0.28 |
Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) | |
---|---|---|
6-Week Change Work activities | 6-Week Change General health perception | |
Lidocaine | 2.71 | -0.004 |
Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
38 other studies available for lidocaine and Amaurosis
Article | Year |
---|---|
Correlation between sub-Tenon's anesthesia and transient amaurosis during ophthalmic surgery.
Topics: Anesthesia, Local; Anesthetics, Local; Blindness; Humans; Lidocaine; Phacoemulsification; Prospectiv | 2020 |
Incidence and impact factors of intraoperative loss of light perception under sub-Tenon's anesthesia in patients with macular diseases.
Topics: Aged; Anesthesia, Local; Anesthetics, Combined; Anesthetics, Local; Blindness; Bupivacaine; Epiretin | 2019 |
A sudden total loss of vision after routine cataract surgery.
Topics: Anesthesia, Local; Anti-Bacterial Agents; Blindness; Cataract; Cataract Extraction; Epinephrine; Fem | 2013 |
Change in flash visual evoked potentials in New Zealand albino rabbits after sub-tenon's anesthesia.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Blindness; Bupivacaine; Evoked Potentials, Visual; F | 2017 |
Retrobulbar hemorrhage and prasugrel.
Topics: Anesthetics, Local; Blindness; Diabetic Retinopathy; Eye Pain; Female; Humans; Laser Coagulation; Li | 2016 |
Transient amaurosis with intracameral lidocaine.
Topics: Anesthetics, Local; Blindness; Humans; Injections, Intraocular; Iridectomy; Lidocaine; Male | 2009 |
Transient, complete loss of vision secondary to posterior diffusion of an ophthalmic viscosurgical device-lidocaine solution during complicated phacoemulsification.
Topics: Aged; Anesthetics, Local; Blindness; Diffusion; Female; Humans; Hyaluronic Acid; Intraoperative Comp | 2009 |
Ocular complications after inferior alveolar nerve block: a case report.
Topics: Adult; Anesthesia, Dental; Anesthetics, Local; Blindness; Confusion; Diplopia; Dizziness; Female; Hu | 2010 |
Purtscher-like retinopathy after retrobulbar anaesthesia in a patient with an intracanal mass.
Topics: Adult; Anesthesia, Local; Anesthetics, Local; Blindness; Cataract Extraction; Evoked Potentials, Vis | 2010 |
Pain management in blind, painful eyes: clinical experience with retrobulbar alcohol injection in 4 cases.
Topics: Aged; Aged, 80 and over; Anesthetics, Local; Blindness; Ethanol; Eye Pain; Female; Glaucoma, Neovasc | 2011 |
Transient bilateral blindness in a patient after cardiac surgery.
Topics: Anesthetics, Local; Blindness; Cardiac Surgical Procedures; Humans; Lidocaine; Male; Middle Aged | 2011 |
The neuroprotective effects of lidocaine and methylprednisolone in a rat model of retinal ischemia-reperfusion injury.
Topics: Anesthetics, Local; Animals; Anti-Inflammatory Agents; Blindness; Electroretinography; Intraocular P | 2012 |
Temporary blindness and ophthalmoplegia due to local anesthetic infiltration of the nasal septum.
Topics: Adult; Anesthetics, Local; Blindness; Humans; Lidocaine; Male; Nasal Septum; Ophthalmoplegia | 2012 |
Neurological picture: bilateral optic neuropathy following unilateral retrobulbar anaesthesia: a case report.
Topics: Aged, 80 and over; Amides; Anesthesia, Spinal; Anesthetics, Local; Blindness; Cataract Extraction; H | 2013 |
Consequence of perforation during peribulbar anesthesia in an only eye.
Topics: Aged; Anesthesia, Local; Anesthetics, Combined; Anesthetics, Local; Blindness; Bupivacaine; Eye Inju | 2003 |
Pediatric cataract surgery in Nepal.
Topics: Adolescent; Anesthesia, General; Anesthetics, Dissociative; Anesthetics, Local; Blindness; Cataract; | 2004 |
Recovery of nerve injury-induced alexia for Braille using forearm anaesthesia.
Topics: Aged; Anesthetics, Local; Blindness; Brachial Plexus; Dyslexia; Forearm; Hand; Humans; Lidocaine; Li | 2008 |
Stellate ganglion block in treatment of total blindness due to quinine.
Topics: Abortion, Criminal; Adolescent; Autonomic Nerve Block; Blindness; Epinephrine; Female; Fundus Oculi; | 1967 |
Blindness as a complication of rhinosurgery.
Topics: Adult; Blindness; Female; Humans; Lidocaine; Male; Middle Aged; Nasal Septum; Norepinephrine; Ophtha | 1981 |
Transient diplopia as a result of block injections. Mandibular and posterior superior alveolar.
Topics: Adult; Anesthesia, Dental; Anesthetics, Local; Blindness; Diplopia; Dizziness; Female; Humans; Lidoc | 1997 |
Bilateral amaurosis following peribulbar anesthesia.
Topics: Aged; Anesthesia, Local; Anesthetics, Combined; Anesthetics, Local; Blindness; Bupivacaine; Glaucoma | 1998 |
Loss of vision: a manifestation of TURP syndrome. A case report.
Topics: Aged; Anesthesia, Spinal; Anesthetics, Local; Blindness; Glycine; Humans; Hypotonic Solutions; Lidoc | 1998 |
Cerebral arterial gas embolism by helium: an unusual case successfully treated with hyperbaric oxygen and lidocaine.
Topics: Adult; Anti-Arrhythmia Agents; Blindness; Cerebral Arteries; Embolism, Air; Helium; Humans; Hyperbar | 2000 |
Central retinal artery occlusion after a local anesthetic with adrenaline on nasal mucosa.
Topics: Acute Disease; Aged; Anesthetics, Local; Blindness; Drug Combinations; Epinephrine; Humans; Lacrimal | 2000 |
Temporary bilateral blindness after acute lidocaine toxicity.
Topics: Acute Disease; Adult; Anesthetics, Local; Blindness; Female; Fractures, Bone; GABA Modulators; Hand | 2002 |
Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting corticosteroid suspensions in combination with other drugs: I. Clinical studies.
Topics: Adult; Anesthesia, General; Blindness; Capillaries; Choroid; Delayed-Action Preparations; Embolism; | 1978 |
[Temporary amaurosis from retrobulbar lidocaine injection in late glaucoma patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, Local; Blindness; Female; Glaucoma, Angle-Cl | 1991 |
Temporary conduction block of optic nerve after retrobulbar anesthesia.
Topics: Adult; Blindness; Evoked Potentials, Visual; Female; Humans; Lidocaine; Male; Middle Aged; Neural Co | 1990 |
Visual loss following intranasal injection.
Topics: Adult; Anesthesia, Local; Blindness; Humans; Injections, Subcutaneous; Lidocaine; Male; Nose Disease | 1989 |
Transient central retinal artery occlusion and contralateral amaurosis after retrobulbar anesthetic injection.
Topics: Aged; Anesthesia, Local; Blindness; Bupivacaine; Female; Humans; Injections; Lidocaine; Optic Nerve | 1989 |
Visual acuity increased by stellate ganglion block. Case reports.
Topics: Aged; Autonomic Nerve Block; Blindness; Female; Humans; Lidocaine; Macular Degeneration; Male; Middl | 1987 |
[Unilateral permanet brutal loss of the vision after an endonasal submucous injection of an anesthetic compound].
Topics: Adult; Anesthetics; Blindness; Humans; Injections; Lidocaine; Male; Tetracaine | 1968 |
[Iatrogenic lesion in ophthalmologic anesthesia].
Topics: Adult; Aged; Anesthesia, General; Anesthesia, Local; Anesthetics; Anesthetics, Local; Atropine; Blin | 1972 |
Transient neurological complications following mandibular nerve block.
Topics: Abducens Nerve; Adult; Anesthesia, Dental; Anesthesia, Local; Blindness; Facial Paralysis; Humans; L | 1972 |
Cortical blindness following convulsions and fever in Nigerian children.
Topics: Anti-Bacterial Agents; Anticonvulsants; Blindness; Blood Transfusion; Bronchopneumonia; Cerebral Cor | 1970 |
Visual loss following tonsillectomy; possible association with injections in tonsillar fossae.
Topics: Blindness; Carotid Arteries; Child; Humans; Injections; Lidocaine; Male; Methylprednisolone; Penicil | 1968 |
[On trsnsitory amauroses in retrobulbar and stomatologic local antsthesia].
Topics: Adult; Aged; Anesthesia, Dental; Anesthesia, Local; Blindness; Female; Glaucoma; Humans; Lidocaine; | 1968 |
[Temporary blindness following retrobulbar anesthesia].
Topics: Adult; Anesthesia, Local; Blindness; Humans; Hyaluronoglucosaminidase; Lidocaine; Male; Nystagmus, P | 1966 |